Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
NCT06337695Phase 3Recruiting
- Sponsor
- American Health Staffing Group
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in diarrhea, Colitis, sponsored by American Health Staffing Group. Started Aug 2026; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
diarrheaColitis
Beyond the preview
Go deeper on NCT06337695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337695.